Beck Peter

CEO Beck Peter sold 18.9K shares ($1.3M) at avg $69.59 on March 2, 2026; holds 884.1K shares post-sale.

Beck Peter, CEO of Rocket Lab, executed 5 separate sales totaling 18.9K shares for $1.3M on 2026-03-02 at prices ranging from $66.83 to $70.03. The blended average price was $69.59, which sits $2.32 below the current price of $71.91 but 25.3% below the 52-week high of $96.30. Post-transaction, Peter retains 884.1K shares, a 2.1% reduction from his prior 902.9K share position. His prior sales at RKLB have shown strong near-term price appreciation (five recent Dec 2025 sales all posted 30-day returns between +62.1% and +70.6%), though the company operates unprofitably ($-18.3M net income on $155.1M quarterly revenue) despite 38.0% annual revenue growth. The multi-tranche structure and modest portfolio reduction size (2.1%) suggest a discrete liquidity event rather than a fundamental conviction shift, occurring as the stock trades well off its 52-week highs.

CEO Peter Beck completely liquidates 2.50M share position (100% of holdings) at RKLB for $141.1M in 14 transactions on Dec 15–16

CEO Peter Beck executed 14 separate sales totaling 2,500,000 shares for $141,105,495.96 over December 15–16, 2025, reducing his holdings to zero and representing a complete exit from his equity stake. The transaction occurred across a blended average price of $56.44, currently 1.7% above the filing date price of $55.49, in a stock that has climbed 21.8% over 30 days and 15.4% over 90 days from depressed levels (trading -19.9% from its 52-week high of $69.27). Beck's prior RKLB trades in September showed positive 30-day and 90-day returns (+34.0%/+10.9% and +39.5%/+15.3%), whereas a complete liquidation by the CEO warrants investor scrutiny of what may have prompted elimination of his entire ownership position, particularly given the company's net loss of $18,257,000 in the latest quarter against $155,080,000 in revenue and accelerating growth (+78.3% annual revenue growth).

CEO Beck Peter sold 18,857 shares of RKLB for $766,569.17 across 3 transactions on 2025-11-24

Beck Peter (CEO) executed 3 separate sales totaling 18,857 shares for $766,569.17 at prices between $40.02 and $41.35, representing a 2.0% reduction in his 921,799-share pre-transaction holdings. The blended average sale price of $40.65 is 4.6% below the current price of $42.60, and significantly higher than the 52-week low of $16.37 but deeply discounted from the 52-week high of $69.27 (now -38.5% from peak). The company remains unprofitable with a net income of $-18,257,000.00 despite strong revenue growth of 78.3% year-over-year and a substantial market cap of $22,755,059,785.80. Notably, his prior 5 open-market sales at RKLB executed on 2025-09-16 all show strong positive 30-day returns ranging from 29.3% to 39.5%, indicating his historical timing at this ticker has favored early sales before gains materialize; the current sale occurs after a 34.0% decline over the prior 30 days, presenting a contrasting pattern worth monitoring as the post-transaction price trajectory develops.

CEO Beck Peter sells 2.50M shares (50% of holdings) for $127.5M across two days at blended avg $50.98

Beck Peter, President, CEO and Chairman of Rocket Lab, executed 8 separate sales totaling 2,500,000 shares for $127,453,446.41 on September 15-16, 2025, reducing his holdings by 50% from 5,000,000 to 2,500,000 shares. The sales spanned prices from $48.04 to $54.96 with a blended average of $50.98, occurring near the company's 52-week high of $54.04. His cross-ticker track record shows 1 prior sell with a 100.00% well-timed rate at the 90-day mark (average 90d return -14.6%), and his sole prior RKLB trade (September 2023 sell) also returned -14.1% at 30 days and -14.6% at 90 days. The current price of $48.08 is -11.0% from the 52-week high and reflects a 6-month momentum context of +72.6% over 90 days against a company that posted negative net income of $-66.4M on revenue of $144.5M in the latest quarter. The scale and timing of a 50% holding liquidation by the CEO, coupled with the company's ongoing unprofitability despite +78.3% annual revenue growth, merit investor scrutiny of management's forward outlook.